{\rtf1\ansi\ansicpg1252\cocoartf949\cocoasubrtf430
{\fonttbl\f0\froman\fcharset0 TimesNewRomanPSMT;\f1\fswiss\fcharset0 ArialMT;}
{\margl1800\margr1600\margt500\margbl1440}
{\pard\sa900\fs50\f0\i Medienmitteilung\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Basel, 19. November 2005\line \line {\b FDA 
Advisory Committee Affirms Safety of Tamiflu in Children} \par}{\pard\f0\li440\ri0\sl360\fs22 - PDF 
Dokument ( http://www.roche.com/med_mbt_191105.pdf) (nur in Englisch)\line \par}\line {\pard\f0\li0\ri0\sa360\sl360\fs22 Basel, 
18. November 2005\line \line {\b Aktuelle 
Informationen zu Tamiflu} \par}{\pard\f0\li440\ri0\sl360\fs22 - PDF 
Dokument ( http://www.roche.com/med_mbt181105-d.pdf)\par}\line {\pard\f0\li0\ri0\sa360\sl360\fs22 \par}
{\pard \par}
{\pard\sb180\f1\fs22 {\b F. Hoffmann-La Roche Ltd}\line 4070 Basel\line Switzerland \par}
{\pard\sb180\f1\fs22 Corporate Communications\line Roche Group Media Relations \par}
{\pard\sb180\f1\fs22 Tel. +41 61 688 88 88\line Fax +41 61 688 27 75\line www.roche.com \par}
}